Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% have a master's degree, and 5% possess a doctoral degree [1] Salary Changes - Among company secretaries with over two years of tenure, the largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The highest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary of company secretaries in the medical consumables sector is 817,000 yuan [2] - Salary distribution among company secretaries is as follows: below 500,000 yuan (30%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (27%), and above 2,000,000 yuan (2%) [2] - The top three highest-paid company secretaries are: Gong Xingliang from Nanwei Medical (2.2161 million yuan), Zhu Yu from Microelectrophysiology (1.6764 million yuan), and Lin Qing from Weigao Orthopedics (1.6142 million yuan) [2] Age and Education Distribution - The age distribution of company secretaries shows that those aged 40-50 constitute 45%, while those over 50 account for 14%, and those aged 30-40 make up 36% [1] - The educational background of company secretaries is as follows: 7% have an associate degree, 45% hold a bachelor's degree, 43% possess a master's degree, and 5% have a doctoral degree [1] Salary Changes - The largest salary decrease was observed for Bai Xue from Xishan Technology, with a year-on-year decline of 54.09% [2] - The largest salary increase was recorded for Chen Bin from Weili Medical, with a year-on-year increase of 191.72% [2]

Core Viewpoint - The article provides a comprehensive overview of the Chinese biomedical materials industry, highlighting key listed companies, their business segments, revenue projections, and strategic planning for future growth. Group 1: Overview of Listed Companies - The A-share listed companies in the biomedical materials sector include Guocera Materials, Weigao Orthopedics, Haohai Biological Technology, Lepu Medical, Lanfang Medical, and Xinmai Medical [1] - The industry is characterized by a diverse range of companies focusing on various segments such as biocomposite materials, biopolymers, and biometals [2][3] Group 2: Revenue Projections - For 2024, key revenue figures for selected companies include: - Guocera Materials: 40.47 billion CNY from dental ceramics and biomedical materials [4] - Weigao Orthopedics: 14.51 billion CNY from orthopedic implants [10] - Lepu Medical: 61.03 billion CNY from cardiovascular materials [5] - The overall revenue for the biomedical materials sector is projected to grow, driven by increasing demand for advanced medical solutions [11] Group 3: Business Layout and Performance - Companies like Aojing Medical, Weigao Orthopedics, and Dabo Medical derive nearly 100% of their revenue from biomedical materials, indicating a focused business strategy [9] - The production and sales rates for biomedical materials are generally below 100%, with companies like Aojing Medical and Weigao Orthopedics showing lower production efficiency [11] Group 4: Strategic Planning and Innovation - Leading companies are focusing on technological innovation, market expansion, and integration of the supply chain to maintain competitive advantages [13] - Companies such as Guocera Materials and Weigao Orthopedics are investing in R&D and international market penetration to enhance their product offerings and market share [14][15]

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 8月4日，沪深两融数据显示，奥精医疗获融资买入额0.15亿元，居两市第929位，当日融资偿还额0.11亿 元，净买入370.38万元。 最近三个交易日，31日-4日，奥精医疗分别获融资买入0.14亿元、0.11亿元、0.15亿元。 ...

Group 1 - On August 1, the financing buy-in amount for Aojing Medical was 0.11 billion, ranking 1081st in the two markets, with a financing repayment amount of 0.12 billion and a net sell of 1.276 million [1] - Over the last three trading days, from July 30 to August 1, Aojing Medical received financing buy-ins of 0.11 billion, 0.14 billion, and 0.11 billion respectively [1] Group 2 - On the same day, the securities lending saw a sell-out of 0.00 thousand shares, resulting in a net sell of 0.00 thousand shares [2]

Group 1 - The core point of the news is that AoJing Medical has seen a notable increase in financing activities, with a net buy of 3.8958 million yuan over the last three trading days [1] - On July 31, AoJing Medical had a financing buy amount of 0.14 billion yuan, ranking 1144th in the market, with a financing repayment amount of 0.10 billion yuan [1] - Over the last three trading days (July 29-31), the financing buy amounts were 0.13 billion yuan, 0.11 billion yuan, and 0.14 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold [2]

7月30日，沪深两融数据显示，奥精医疗获融资买入额0.11亿元，居两市第1239位，当日融资偿还额0.15 亿元，净卖出335.84万元。 最近三个交易日，28日-30日，奥精医疗分别获融资买入0.13亿元、0.13亿元、0.11亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 ...

通过天眼查大数据分析，奥精医疗科技股份有限公司共对外投资了8家企业，参与招投标项目130次，知 识产权方面有商标信息48条，专利信息134条，此外企业还拥有行政许可21个。 来源：金融界 资金流向方面，今日主力资金净流出1472.89万元，占比成交额18.82%。其中，超大单净流出321.15万 元、占成交额4.1%，大单净流出1151.74万元、占成交额14.72%，中单净流出流入968.61万元、占成交 额12.38%，小单净流入504.27万元、占成交额6.44%。 奥精医疗最新一期业绩显示，截至2025一季报，公司营业总收入4245.97万元、同比减少10.35%，归属 净利润104.15万元，同比减少84.99%，扣非净利润234.15万元，同比减少168.21%，流动比率18.403、速 动比率16.987、资产负债率8.65%。 天眼查商业履历信息显示，奥精医疗科技股份有限公司，成立于2004年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本13555.1584万人民币，实缴资本13555.1584万人民币。公司法定代 表人为胡刚。 金融界消息 截至2025年7月30日收盘，奥精医 ...

7月29日，沪深两融数据显示，奥精医疗获融资买入额0.13亿元，居两市第1162位，当日融资偿还额0.12 亿元，净买入58.76万元。 来源：金融界 最近三个交易日，25日-29日，奥精医疗分别获融资买入0.33亿元、0.13亿元、0.13亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 ...

Group 1 - The latest stock price of Aojing Medical is 19.76 yuan, an increase of 0.24 yuan from the previous trading day [1] - The stock reached a high of 19.90 yuan and a low of 19.35 yuan during the trading session, with a trading volume of 40,088 hands and a transaction amount of 0.78 billion yuan [1] - Aojing Medical specializes in the research, production, and sales of high-end medical devices, including orthopedic implant materials and neurosurgical products, and holds the qualification of a specialized and innovative enterprise [1] Group 2 - On the day of reporting, the net outflow of main funds for Aojing Medical was 2.6681 million yuan, accounting for 0.1% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 4.8744 million yuan [1]